Encompass Health (NYSE:EHC) reported its first-quarter results for 2026 on April 30, beating analyst expectations on both the top and bottom lines. The company, which operates the largest network of inpatient rehabilitation hospitals in the United States, also raised its full-year guidance. Despite the positive numbers, shares moved lower in after-market trading, slipping roughly 1%.
Earnings vs. Estimates
Encompass Health delivered revenue of $1.586 billion for the quarter ended March 31, 2026, exceeding the consensus estimate of $1.584 billion. On an adjusted (non-GAAP) basis, earnings per share came in at $1.60, beating the analyst forecast of $1.51 by a solid margin.
Key numbers versus expectations:
- Revenue: $1.586 billion actual vs. $1.584 billion estimated (beat)
- Adjusted EPS: $1.60 actual vs. $1.51 estimated (beat)
- Year-over-year revenue growth: +9%
The company’s ability to outpace revenue estimates reflects steady demand for post-acute rehabilitative care, a segment that continues to benefit from an aging population and increased incidence of conditions requiring specialized recovery, such as strokes and neurological disorders.
Market Reaction
Despite the earnings beat and the upward revision to guidance, the stock dipped roughly 1% in after-hours trading. The muted reaction may stem from the fact that the beat on revenue was marginal—less than 0.2% above the consensus. Additionally, with the stock having risen roughly 2.7% over the past month leading into the report, some investors may have already priced in a strong quarter.
Short-term performance context:
- Last week: -1.8%
- Last 2 weeks: -5.2%
- Last month: +2.7%
- After-market (post-earnings): -1.0%
The small post-release decline does not necessarily indicate a loss of confidence. Rather, it could reflect profit-taking after a run-up or a wait-and-see approach as the market digests the company’s updated outlook for the remainder of the year.
Full-Year Guidance and Outlook
Encompass Health raised its full-year guidance, signaling management’s confidence in continued operational momentum. The company now expects:
- Full-year 2026 revenue: approximately $6.489 billion, compared to prior estimates in the range of $6.4 billion.
- Full-year adjusted EPS: now projected at roughly $6.40, up from earlier guidance.
Analysts had already been modeling full-year revenue near $6.49 billion and EPS around $6.02, so the updated guidance aligns closely with current street expectations but edges higher on the earnings side.
For the second quarter of 2026, analysts are currently modeling revenue of about $1.588 billion and adjusted EPS of roughly $1.49, suggesting the company will need to maintain its pace of solid occupancy rates and disciplined cost management to continue outperforming.
Press-Release Highlights
Beyond the headline numbers, the earnings release contained several notable details:
- Encompass Health remains the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 166 hospitals operating across 38 states and Puerto Rico.
- The company continues to treat a wide range of conditions, including stroke recovery, hip fractures, and neurological conditions, as well as post-COVID rehabilitation.
- No major acquisitions or divestitures were disclosed, indicating that growth came from organic patient volume and pricing improvements.
Analyst Views
The post-earnings price action may temper near-term enthusiasm, but the fundamentals remain intact. The raised guidance suggests that management sees sustained demand through the rest of the year. However, with the stock’s recent volatility, analysts will likely be watching the second quarter closely to confirm that the company can deliver on its upgraded targets.
Where to Track Future Performance
For a deeper look into Encompass Health’s historical earnings performance, upcoming projections, and analyst expectations, visit the company’s Earnings Page and Analyst Ratings & Forecast Page for the latest data and estimates.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research or consult with a qualified financial advisor before making investment decisions.